Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.

Tornøe CW, Agersø H, Senderovitz T, Nielsen HA, Madsen H, Karlsson MO, Jonsson EN

British journal of clinical pharmacology10 Nov 2006Cited by 29 (Europe PMC)

PMID17096678PMCIDPMC2000597DOI10.1111/j.1365-2125.2006.02820.xPepBankPUB-17096678

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialMechanism
The model estimated maximal triptorelin stimulation of basal LH pool release at 1330 times basal concentrations.
In plain wordsThe computer model estimated maximal triptorelin stimulation of LH release at 1330 times basal concentrations.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseMaximal triptorelin stimulation of LH release
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Measurements
Maximal LH release stimulation
1330 times basal
triptorelin
Source sentences
Summary
The estimated maximal triptorelin stimulation of the basal LH pool release was 1330 times above basal concentrations, with a potency of 0.047 ng ml(-1).
2 context sentences(design, population, supporting numbers)
Summary · context
All subjects were pooled for the population PK/PD data analysis.
Summary · context
A systematic population PK/PD model-building framework using stochastic differential equations was applied to the data to identify nonlinear dynamic dependencies and to deconvolve the functional feedback interactions of the HPG axis.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1709667801
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialMechanism
The model estimated triptorelin potency for LH pool release at 0.047 ng ml(-1).
In plain wordsThe computer model estimated triptorelin potency for LH release at 0.047 ng ml(-1).
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTriptorelin potency for LH release
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Measurements
Triptorelin potency
0.047 ng ml(-1)
LH pool release
Source sentences
Summary
The estimated maximal triptorelin stimulation of the basal LH pool release was 1330 times above basal concentrations, with a potency of 0.047 ng ml(-1).
2 context sentences(design, population, supporting numbers)
Summary · context
All subjects were pooled for the population PK/PD data analysis.
Summary · context
A systematic population PK/PD model-building framework using stochastic differential equations was applied to the data to identify nonlinear dynamic dependencies and to deconvolve the functional feedback interactions of the HPG axis.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1709667802

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01656161

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Debiopharm International SAn = 120Jul 2012 to Aug 2013

Prostate Cancer

Trial page ClinicalTrials.govUpdated 15 Sept 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:34 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC